Targeting the MTAP-PRMT5 axis: from synthetic lethality to emerging therapeutic opportunities
Abstract
Homozygous deletion of methylthioadenosine phosphorylase (MTAP), one of the most frequent somatic copy-number alterations in cancer, creates a context of synthetic lethal vulnerability. MTAP loss leads to the accumulation of 5'-methylthioadenosine (MTA), which partly inhibits protein arginine methyltransferase 5 (PRMT5), and induces a dependency on residual PRMT5 activity; a dependency that can be pharmacologically exploited. This review describes the MTAP-PRMT5 synthetic lethal axis from molecular biology to clinical translation. First-generation nonselective PRMT5 inhibitors were limited by hematological toxicity and reduced potency in MTA-rich environments. Second-generation MTA-cooperative inhibitors, which overcome these constraints by selectively stabilizing the inactive PRMT5-MTA complex, are characterized by tumor selectivity. Early-phase clinical data for MTA cooperative PRMT5 inhibitors showed encouraging signals of efficacy with manageable safety profiles in early-phase trials, establishing clinical proof of concept. Various agents have now entered the next steps of clinical development either alone or in combination. In this review we also discuss the biomarker challenges, essential to patient selection, including the limitations of different methods, as well as emerging resistance mechanisms to PRMT5 inhibitors. Molecular testing standardization, pharmacodynamic endpoint integration, and prospective resistance characterization are identified as priorities for next phases of development of PRMT5 inhibition.
Related
- Gut-liver axis in liver pre-metastatic niche formation: immune networks, microbial, and metabolic and emerging therapeutic opportunities
- Targeting Aromatase and HDACs in Hormone Receptor-Positive Breast Cancer: Molecular Interplay, Endocrine Resistance and Therapeutic Opportunities.
- DNA/RNA Methylation-Driven Coronary Microvascular Dysfunction: Emerging Pathogenic Mechanisms and Therapeutic Opportunities for Heart Failure in Diabetes
- Targeting UFMylation in Cancer: Emerging Roles in Cancer Stem Cell Regulation and Therapeutic Targeting
- Explainable/interpretable artificial intelligence and knowledge graph neural network for synthetic lethality prediction: overview, challenges, and future directions
BibTeX
@article{genoud2026targeting,
title = {{Targeting the MTAP-PRMT5 axis: from synthetic lethality to emerging therapeutic opportunities}},
author = {Vassilis Genoud and Maxime Borgeaud and Mihaela Aldea and Thibaud Koessler and Alfredo Addeo},
journal = {The Oncologist},
year = {2026},
month = oct,
doi = {10.1093/oncolo/oyag425},
url = {https://doi.org/10.1093/oncolo/oyag425},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Targeting the MTAP-PRMT5 axis: from synthetic lethality to emerging therapeutic opportunities
AU - Vassilis Genoud
AU - Maxime Borgeaud
AU - Mihaela Aldea
AU - Thibaud Koessler
AU - Alfredo Addeo
PY - 2026
DA - 2026/10/22
JO - The Oncologist
DO - 10.1093/oncolo/oyag425
UR - https://doi.org/10.1093/oncolo/oyag425
AB - Homozygous deletion of methylthioadenosine phosphorylase (MTAP), one of the most frequent somatic copy-number alterations in cancer, creates a context of synthetic lethal vulnerability. MTAP loss leads to the accumulation of 5'-methylthioadenosine (MTA), which partly inhibits protein arginine methyltransferase 5 (PRMT5), and induces a dependency on residual PRMT5 activity; a dependency that can be pharmacologically exploited. This review describes the MTAP-PRMT5 synthetic lethal axis from molecular biology to clinical translation. First-generation nonselective PRMT5 inhibitors were limited by hematological toxicity and reduced potency in MTA-rich environments. Second-generation MTA-cooperative inhibitors, which overcome these constraints by selectively stabilizing the inactive PRMT5-MTA complex, are characterized by tumor selectivity. Early-phase clinical data for MTA cooperative PRMT5 inhibitors showed encouraging signals of efficacy with manageable safety profiles in early-phase trials, establishing clinical proof of concept. Various agents have now entered the next steps of clinical development either alone or in combination. In this review we also discuss the biomarker challenges, essential to patient selection, including the limitations of different methods, as well as emerging resistance mechanisms to PRMT5 inhibitors. Molecular testing standardization, pharmacodynamic endpoint integration, and prospective resistance characterization are identified as priorities for next phases of development of PRMT5 inhibition.
SN - 1083-7159
SN - 1549-490X
ER -